Iovance Biotherapeutics, Inc. (IOVA)
Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel G. Kirby - Chief Commercial Officer Frederick G.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago.
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revised downward. The impending approval of a rival therapy in the advanced melanoma space - Replimmune's RP1 - is another cause for concern.
Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity
Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance. Management expects a rebound in Q2 with resumed full manufacturing capacity and increased commercial infusions, potentially leading to a positive earnings surprise. Despite the Q1 setback, Iovance's early adoption, expanding treatment network, and international regulatory prospects indicate strong long-term growth potential.
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Brian Gastman - EVP, Medical Affairs Conference Call Participants Andrew Tsai - Jefferies Tyler Van Buren - TD Cowen Salim Syed - Mizuho Andrea Newkirk - Goldman Sachs Yanan Zhu - Wells Fargo Colleen Kusy - Baird Peter Lawson - Barclays Reni Benjamin - Citizens Operator Good day and thank you for standing by. Welcome everyone to the Iovance Biotherapeutics First Quarter 2025 Financial Results Conference Call.
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago.
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
Iovance Biotherapeutics (IOVA 4.38%) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or metastatic melanoma.
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins.
